Literature DB >> 27628460

Monitoring anticoagulation with argatroban in critically ill patients: activated partial thromboplastin time versus diluted thrombin time.

Cornelius Keyl1, Cornelius Lehane, Emanuel Zimmer, Dietmar Trenk.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27628460     DOI： 10.1160/TH16-06-0468

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN： 0340-6245            Impact factor:   5.249


× No keyword cloud information.
  3 in total

1.  Evaluation of intravenous direct thrombin inhibitor monitoring tests: Correlation with plasma concentrations and clinical outcomes in hospitalized patients.

Authors:  Jacob T Beyer; Stuart E Lind; Sheila Fisher; Toby C Trujillo; Michael F Wempe; Tyree H Kiser
Journal:  J Thromb Thrombolysis       Date:  2020-02       Impact factor: 2.300

2.  Monitoring of argatroban and lepirudin anticoagulation in critically ill patients by conventional laboratory parameters and rotational thromboelastometry - a prospectively controlled randomized double-blind clinical trial.

Authors:  Martin Beiderlinden; Patrick Werner; Astrid Bahlmann; Johann Kemper; Tobias Brezina; Maximilian Schäfer; Klaus Görlinger; Holger Seidel; Peter Kienbaum; Tanja A Treschan
Journal:  BMC Anesthesiol       Date:  2018-02-09       Impact factor: 2.217

3.  Caution in Using the Activated Partial Thromboplastin Time to Monitor Argatroban in COVID-19 and Vaccine-Induced Immune Thrombocytopenia and Thrombosis (VITT).

Authors:  Susan Guy; Steve Kitchen; Michael Makris; Rhona M Maclean; Giorgia Saccullo; Joost J Vanveen
Journal:  Clin Appl Thromb Hemost       Date:  2021 Jan-Dec       Impact factor: 2.389
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.